Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum

We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shaohua, Li, Hui, Yang, Xiqin, Wang, Wei, Huang, Aixue, Li, Jie, Qin, Xingliang, Li, Fei, Lu, Guanyi, Ding, Hongmei, Su, Xueting, Hou, Lvbin, Xia, Wei, Shi, Ming, Zhang, Hongwen, Zhao, Qiang, Dong, Jie, Ge, Xingfeng, Sun, Leqiao, Bai, Chenjun, Wang, Chaonan, Shen, Xuelian, Fang, Tao, Wang, Fusheng, Zhang, Heqiu, Shao, Ningsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496339/
https://www.ncbi.nlm.nih.gov/pubmed/25826090
_version_ 1782380382191091712
author Li, Shaohua
Li, Hui
Yang, Xiqin
Wang, Wei
Huang, Aixue
Li, Jie
Qin, Xingliang
Li, Fei
Lu, Guanyi
Ding, Hongmei
Su, Xueting
Hou, Lvbin
Xia, Wei
Shi, Ming
Zhang, Hongwen
Zhao, Qiang
Dong, Jie
Ge, Xingfeng
Sun, Leqiao
Bai, Chenjun
Wang, Chaonan
Shen, Xuelian
Fang, Tao
Wang, Fusheng
Zhang, Heqiu
Shao, Ningsheng
author_facet Li, Shaohua
Li, Hui
Yang, Xiqin
Wang, Wei
Huang, Aixue
Li, Jie
Qin, Xingliang
Li, Fei
Lu, Guanyi
Ding, Hongmei
Su, Xueting
Hou, Lvbin
Xia, Wei
Shi, Ming
Zhang, Hongwen
Zhao, Qiang
Dong, Jie
Ge, Xingfeng
Sun, Leqiao
Bai, Chenjun
Wang, Chaonan
Shen, Xuelian
Fang, Tao
Wang, Fusheng
Zhang, Heqiu
Shao, Ningsheng
author_sort Li, Shaohua
collection PubMed
description We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR, IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN. Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC.
format Online
Article
Text
id pubmed-4496339
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44963392015-07-15 Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum Li, Shaohua Li, Hui Yang, Xiqin Wang, Wei Huang, Aixue Li, Jie Qin, Xingliang Li, Fei Lu, Guanyi Ding, Hongmei Su, Xueting Hou, Lvbin Xia, Wei Shi, Ming Zhang, Hongwen Zhao, Qiang Dong, Jie Ge, Xingfeng Sun, Leqiao Bai, Chenjun Wang, Chaonan Shen, Xuelian Fang, Tao Wang, Fusheng Zhang, Heqiu Shao, Ningsheng Oncotarget Research Paper We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR, IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN. Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC. Impact Journals LLC 2015-03-12 /pmc/articles/PMC4496339/ /pubmed/25826090 Text en Copyright: © 2015 Li et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Li, Shaohua
Li, Hui
Yang, Xiqin
Wang, Wei
Huang, Aixue
Li, Jie
Qin, Xingliang
Li, Fei
Lu, Guanyi
Ding, Hongmei
Su, Xueting
Hou, Lvbin
Xia, Wei
Shi, Ming
Zhang, Hongwen
Zhao, Qiang
Dong, Jie
Ge, Xingfeng
Sun, Leqiao
Bai, Chenjun
Wang, Chaonan
Shen, Xuelian
Fang, Tao
Wang, Fusheng
Zhang, Heqiu
Shao, Ningsheng
Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title_full Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title_fullStr Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title_full_unstemmed Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title_short Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum
title_sort vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-emsa-selex to clinic patient serum
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496339/
https://www.ncbi.nlm.nih.gov/pubmed/25826090
work_keys_str_mv AT lishaohua vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT lihui vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT yangxiqin vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT wangwei vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT huangaixue vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT lijie vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT qinxingliang vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT lifei vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT luguanyi vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT dinghongmei vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT suxueting vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT houlvbin vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT xiawei vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT shiming vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT zhanghongwen vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT zhaoqiang vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT dongjie vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT gexingfeng vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT sunleqiao vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT baichenjun vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT wangchaonan vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT shenxuelian vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT fangtao vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT wangfusheng vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT zhangheqiu vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum
AT shaoningsheng vasorinisapotentialserumbiomarkeranddrugtargetofhepatocarcinomascreenedbysubtractiveemsaselextoclinicpatientserum

Ejemplares similares